JenaValve Technology, a Germany-based medical device company, has received CE mark approval for its second-generation transapical transcatheter aortic valve implantation (TAVI) system, designed to treat severe aortic valve stenosis in elderly high-risk patients.

The TAVI system incorporates both the Cathlete delivery system and the JenaValve heart valve prosthesis.

The approval is based on a 73-patient prospective multicentre uncontrolled clinical trial, which supported the safety and efficacy of the JenaValve system.

The primary endpoint of the trial was the 30-day mortality rate, while the secondary endpoints included the rate of successful implantation, as well as further parameters for performance and safety of the prosthetic heart valve.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.